<DOC>
	<DOCNO>NCT00990938</DOCNO>
	<brief_summary>Phase 1 , randomize , double-blind , placebo-controlled , dose-escalation study 3 dose level IMO-2125 combination standard weight base ribavirin ( investigational treatment arm ) placebo combination ribavirin ( RBV ) . Each cohort 15 patient randomize 4:1 receive investigational treatment arm ( 12 patient ) placebo RBV arm ( 3 patient ) .</brief_summary>
	<brief_title>Study Combination Treatment With IMO-2125 Ribavirin Na√Øve Hepatitis C-infected , Genotype 1 Patients</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , dose-escalation study 3 dose level IMO-2125 combination standard ribavirin placebo plus ribavirin . Each cohort randomize 4:1 receive investigational treatment arm placebo ribavirin . Three vary dose level IMO-2125 include . In arm , ribavirin dose base patient weight . Approximately 50 patient enrol France Russia . Patients provide informed consent prior screen procedure perform . Screening occur within 21 day prior randomization . Enrolled patient qualify proceed successfully screening period randomize receive 4 week either investigational treatment arm ( IMO-2125 ribavirin ) placebo ribavirin , 4 week follow-up period . Patients randomize investigational treatment arm receive one 3 dose level IMO 2125 SC weekly ; patient receive dose throughout 4 week treatment . In addition IMO-2125 treatment also receive daily ribavirin , give base patient weight take twice daily total 4 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Documented genotype 1 HCVpositive document detectable plasma viral concentration &gt; 10,000 IU/mL Positive test HIV HbsAg Inadequate bone marrow , liver , renal function Treatment IFNbased experimental antiviral therapy prior current Other significant medical disease Concurrent plan treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>